<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273608</url>
  </required_header>
  <id_info>
    <org_study_id>HEPA-Taiwan-001</org_study_id>
    <nct_id>NCT03273608</nct_id>
  </id_info>
  <brief_title>Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients</brief_title>
  <official_title>Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety &amp; Efficacy Registry in Taiwan (SUPER- Taiwan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter registry is to gather the safety, efficacy and survival data&#xD;
      in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order&#xD;
      to provide clinical evidence in HCC management to physicians in the region, and to support&#xD;
      the application of deTACE in treating advanced HCC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this multicenter registry is to gather the safety, efficacy and survival data&#xD;
      in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order&#xD;
      to provide clinical evidence on deTACE in HCC management to physicians in the region, and to&#xD;
      support the application of in treating advanced HCC patients.&#xD;
&#xD;
        1. Primary Objective:&#xD;
&#xD;
           To collect 1-year overall survival of chemoembolization with drug-eluting microsphere in&#xD;
           intermediate and advanced HCC patients in Taiwan.&#xD;
&#xD;
        2. Secondary Objectives:&#xD;
&#xD;
             1. To evaluate the overall tumor response of chemoembolization with drug-eluting&#xD;
                microsphere in intermediate and advanced HCC patients. The tumor response is&#xD;
                according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)&#xD;
                criteria.&#xD;
&#xD;
             2. To evaluate the local tumor response (in the tumor(s) treated with drug-eluting&#xD;
                microsphere) by chemoembolization with drug-eluting microsphere in intermediate and&#xD;
                advanced HCC patients.&#xD;
&#xD;
             3. To evaluate the safety profile of chemoembolization with drug-eluting microsphere&#xD;
                in intermediate and advanced HCC patients.&#xD;
&#xD;
        3. Exploratory Objectives:&#xD;
&#xD;
             1. To evaluate the downstaging and downsizing potential of chemoembolization with&#xD;
                drug-eluting microsphere in intermediate and advanced HCC patients to within Milan&#xD;
                Criteria and to within Resection margin.&#xD;
&#xD;
             2. To collect time-to-progression (TTP) and progress-free-survival (PFS) data of&#xD;
                chemoembolization with drug-eluting microsphere in intermediate and advanced HCC&#xD;
                patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>To define all participants from the day of the first HepaSphere Treatment until end of study or death is reported, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis under CT/ MRI and will be presented as %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse event will be accessed according to CTCAE 4.0 after treatments until end of study or death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Objectives, Time-To-Progression (TTP)</measure>
    <time_frame>1 year</time_frame>
    <description>To define all participants from the day of the first HepaSphere Treatment until tumor progression or death is first reported, whichever comes first.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Objectives, Downstaging</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor staging will be accessed according to BCLC staging system and Milan criteria, and will be reviewed at follow-up until end of study or death.</description>
  </other_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC&#xD;
        Patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to&#xD;
        be entered into the study:&#xD;
&#xD;
          -  Age 20 or older.&#xD;
&#xD;
          -  Patient has signed informed consent.&#xD;
&#xD;
          -  Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least&#xD;
             one of the following method:&#xD;
&#xD;
               -  Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement&#xD;
                  washout of at least one solid liver lesion &gt; 1 cm.&#xD;
&#xD;
               -  Contrast enhanced computed tomography (CT) with early enhancement and delayed&#xD;
                  enhancement washout of at least one solid liver lesion &gt; 1 cm.&#xD;
&#xD;
               -  Histological confirmation is required for lesions with inconclusive features.&#xD;
&#xD;
          -  Patient must not be suitable for treatment by resection or percutaneous ablation at&#xD;
             time of study entry.&#xD;
&#xD;
               -  Patients not suitable for ablation due to lesion location may be enrolled.&#xD;
&#xD;
               -  Patients with HCC recurrence but not suitable for resection or ablation maybe&#xD;
                  enrolled.&#xD;
&#xD;
          -  Patient MUST be with either BCLC stage B OR C, and meet the following criteria:&#xD;
&#xD;
               -  Stage Child-Pugh A or B AND&#xD;
&#xD;
               -  Performance status ECOG â‰¤ 1 WITH Vascular Invasion or WITHOUT Vascular invasion.&#xD;
&#xD;
          -  Patient has a life expectancy of at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:If patients meet any of the following criteria they may not be entered&#xD;
        into the study:&#xD;
&#xD;
          -  Current or previous treatment with chemo- or radiation therapy or sorafenib or&#xD;
             drug-eluting chemoembolization (deTACE).&#xD;
&#xD;
          -  Patients with concurrent cancer except non-melanomatous skin cancer.&#xD;
&#xD;
          -  Female patients who are pregnant, breastfeeding, or premenopausal and not using an&#xD;
             effective method of contraceptive.&#xD;
&#xD;
          -  Performance status ECOG &gt; 1.&#xD;
&#xD;
          -  Child-Pugh Class C.&#xD;
&#xD;
          -  Occlusive tumor thrombus to the main portal trunk.&#xD;
&#xD;
          -  Active gastrointestinal bleeding.&#xD;
&#xD;
          -  Evidence of uncorrectable bleeding diathesis.&#xD;
&#xD;
          -  Extra-Hepatic spread of the HCC.&#xD;
&#xD;
          -  Encephalopathy not adequately controlled medically.&#xD;
&#xD;
          -  Presence of ascites not controlled medically.&#xD;
&#xD;
          -  Any contraindication for MRI/ CT (eg. metallic implants).&#xD;
&#xD;
          -  Allergy to contrast media that cannot be managed with prophylaxis.&#xD;
&#xD;
          -  Any contraindication to arteriography.&#xD;
&#xD;
          -  Any contraindication for doxorubicin administration.&#xD;
&#xD;
          -  Any contraindication for hepatic embolization. Porto-systemic shunt, or an&#xD;
             arteriovenous shunt that cannot be adequately closed prior to chemoembolization.&#xD;
             Hepatofugal blood flow. Serum creatinine &gt; 2mg/dL. Other condition deemed exclusionary&#xD;
             by physician. Uncorrectable impaired clotting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Hsiang Huang, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Hsiang Huang, M.D. Ph.D.</last_name>
    <phone>+886-2-28757506</phone>
    <email>yhhhuang@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Hsiang Huang, M.D. Ph.D.</last_name>
      <phone>+886-2-28757506</phone>
      <email>yhhuang@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>August 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Professor Yi-Hsiang Huang</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Advanced HCC</keyword>
  <keyword>Unresectable</keyword>
  <keyword>deTACE</keyword>
  <keyword>HepaSphere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

